CCO Management Series
Neurologic Aspects of HIV/AIDS: New Insights and Management Advances
Neurologic Manifestations of HIV Infection |
Module 1 of 3
|
Pathogenesis of Neurologic Complications of HIV |
Module 2 of 3 |
|
CME Program Director: John P. Phair, MD
 
- Katia Cikurel, MD
- David M. Simpson, MD
|
|
|
David M. Simpson, MD, and Katia Cikurel, MD, review neurologic complications of HIV and HAART.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the cell types and cell surface receptors involved in CNS neuropathogenesis
- List models that describe how HIV damages neurons
- Discuss how epidemiology of neurologic complications has evolved during the HAART era
|
Neurologic and Psychiatric Adverse Effects of Antiretroviral Agents |
Module 3 of 3 |
|
CME Program Director: John P. Phair, MD
- Katia Cikurel, MD
- David M. Simpson, MD
|
|
|
David M. Simpson, MD, and Katia Cikurel, MD, review neurologic complications of HAART agents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List antiretrovirals that may have adverse effects on the neurologic system
- Recount the clinical manifestations of antiretroviral side effects on the neurologic system
- Discuss management strategies for these neurologic system side effects
- Describe central nervous system side effects that are related to efavirenz use and techniques to help patients deal with these side effects
|
Interactive Case Challenges
An HIV-Infected Man Who Presents With Subacute Neurologic Symptoms
|
Program Director: John P. Phair, MD
 
- Lydia Estanislao, MD
- Amrit Grewal, MD
- David M. Simpson, MD
|
 |
|
|
Through video clips and text description, make choices regarding diagnostic procedures and treatment options for a man who presents with visual field defect on the right side of each eye, and weakness of the right arm and leg.
Learning Objectives
Upon completion of this activity, participants should be able to:
List various diagnostic tests used to identify PML in HIV-infected patients Outline advantages and disadvantages of various treatment options for PML in HIV-infected patients Describe the clinical presentation of progressive multifocal leukoencephalopathy (PML) in the HIV population
|
A Man With Advanced AIDS With an Episode of Loss of Consciousness
|
Program Director: John P. Phair, MD
- Lydia Estanislao, MD
- Amrit Grewal, MD
- David M. Simpson, MD
|
|
|
|
Test your ability to work-up and manage of a patient with a 1-week history of fever and headache who is found unconscious.
Learning Objectives
Upon completion of this activity, participants should be able to:
List advantages and disadvantages of diagnostic tests used to identify and confirm CNS toxoplasmosis Discuss treatment options for seizure and CNS toxoplasmosis in HIV-infected patients Describe symptoms and laboratory findings associated with HIV-related CNS toxoplasmosis
|
An HIV-Infected Man Who Presents With Leg Weakness, Stiffness, and Sensory Disturbances
|
Program Director: John P. Phair, MD
- Lydia Estanislao, MD
- David M. Simpson, MD
- Susama Verma, MD
|
|
|
Compare your diagnosis and management decisions with those of our faculty as you evaluate a patient who presents with a gradual onset of leg weakness and stiffness, sensory disturbances, urinary disturbances, and erectile dysfunction.
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss antiretroviral treatment considerations for patients with HIV-associated myelopathy. Describe the signs and symptoms of myelopathy, and the neurologic examination of a patient with presumptive myelopathy. List diagnostic tests used in establishing a diagnosis of HIV-associated myelopathy.
|
Animation
HIV, Antiretrovirals, and the Blood Brain Barrier
 |
|
A 3D animation illustrating the anatomy and functions of the blood-brain barrier, and its role in influencing CNS penetration of HIV and antiretrovirals.
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash (.swf) |
File size: 848 KB
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|